Live Breaking News & Updates on Clinical Collaborative Research Organization

Mar 8, 2021 8:55am
Researchers from Harvard University and Massachusetts General Hospital suggested JAK inhibitors may be useful in treating Alzheimer s after using machine learning to model the response of brain neural cells to a variety of drugs. (sdecoret/iStock/Getty Images Plus)
Could janus kinase (JAK) inhibitors like Eli Lilly’s rheumatoid arthritis drug Olumiant be repurposed to treat Alzheimer’s disease? Researchers at Harvard University and Massachusetts General Hospital have set out to find the answer to that question with a new clinical trial that was born from artificial intelligence.
The researchers used a type of AI called machine learning to identify existing drugs that might be able to prevent neuronal death in Alzheimer’s. The screen pulled up a list of 15 FDA-approved drugs as candidates for repurposing in Alzheimer’s, and five of them were JAK inhibitors, they reported in the journal Nature Communications. ....

United States , Fort Lauderdale , Harvard University , Paraza Pharma , Eli Lilly , Nature Communications , Clinical Collaborative Research Organization , Holy Cross Health In Fort Lauderdale , Researchers At Harvard University , Brown University , Massachusetts General Hospital , Mass General , Holy Cross Health , Xcel Therapeutics , Harvard Medical School , Jak Inhibitors , Alzheimer 039 S , Academic Research , Machine Learning , Artificial Intelligence , Drug Repurposing , ஒன்றுபட்டது மாநிலங்களில் , கோட்டை லாடர்டேல் , ஹார்வர்ட் பல்கலைக்கழகம் , எலி லில்லி , இயற்கை தகவல்தொடர்புகள் ,